$599
Zegalogue Receives Positive CHMP Opinion
Zealand Pharma announced CHMP adopted a positive opinion recommending granting marketing authorization for Zegalogue (dasiglucagon) for the treatment of severe hypoglycemia in adults, adolescents, and children with diabetes aged 6 years and over. A final decision from the European Commission is expected within ~3 months. Below, FENIX provides brief insight into Zegalogue’s market potential.